Modulation of dopamine D1 receptors via histamine H3 receptors is a novel therapeutic target for Huntington’s disease
David Moreno‐Delgado, Mar Puigdellívol, Estefanía Moreno, Mar Rodríguez-Ruiz, Joaquín A. Botta, Paola Gasperini, Anna Chiarlone, Lesley A. Howell, Marco Scarselli, Vicent Casadó, Antoni Cortés, Sergi Ferré, Manuel Guzmán, Carmen Lluís, Jordi Alberch, , Peter James McCormick
This study identifies D1R-H3R heteromers as a therapeutic target for Huntington’s disease by showing their role in dopamine signaling and their modulation by H3R antagonists.
eLife · Jun 8, 2020Peer-reviewedNeuroscience